Search clinical trials for: Placebo insulin degludec

Total 56431 results

Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Spain, France, Norway, Romania
Novo Nordisk A/S

Completed

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Safety and Tolerability of NN9068 in Healthy Male Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt, Morocco, Indonesia, Tunisia, Vietnam
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes (4T)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Ireland
Novo Nordisk A/S

Completed

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone

Diabetes Mellitus, Type 2 | Diabetes

Iran, Islamic Republic of
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Russian Federation, Ukraine
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan (RESILIENT)

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

Diabetes

Japan
Novo Nordisk A/S

Completed

A Comparison Between Two Formulations of NN5401 in Healthy Subjects

Healthy | Diabetes

United States
Novo Nordisk A/S

Completed

Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon

Diabetes Mellitus, Type 2

Lebanon
Novo Nordisk A/S

Completed

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice (ARISE)

Diabetes Mellitus, Type 2

Malaysia, South Africa, Philippines, Australia, India, Saudi Arabia
Novo Nordisk A/S

Completed

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Poland, Croatia, Germany, Turkey, Slovakia, Bulgaria, Romania, Algeria, Czechia, Ukraine
Novo Nordisk A/S

Completed

Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S
HNEC TEST

Completed

A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) (DUAL™ I China)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia

Diabetes Mellitus, Type 2

Russian Federation
Novo Nordisk A/S

Terminated

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin (ONWARDS 2)

Diabetes Mellitus, Type 2

Poland, United States, Japan, Korea, Republic of, Germany, Bulgaria, South Africa, Portugal, Ukraine
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects

Healthy

China
Novo Nordisk A/S

Completed

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes

India, Serbia, Bulgaria, Australia, Korea, Republic of, Thailand, Turkey, United Arab Emirates, Hungary
Novo Nordisk A/S

Completed

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs (DUAL™ II Japan)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs

Diabetes Mellitus, Type 2 | Diabetes

Morocco, Tunisia, Algeria, South Africa, Egypt
Novo Nordisk A/S

Completed

Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) (DUAL™ II China)

Diabetes Mellitus, Type 2 | Diabetes

Hong Kong, China
Novo Nordisk A/S

Completed

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes (DUAL™ I)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Italy, Mexico, Russian Federation, Slovakia, Spain, Canada, Taiwan, Finland, Hungary, Malaysia, South Africa, United Kingdom, Germany, Australia, Thailand, Ireland, Puerto Rico, Singapore
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China (CN-TREAT)

Diabetes Mellitus, Type 2

China
prof dr Pieter Gillard
University Hospital, Antwerp

Completed

Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec (GLADE)

Type 1 Diabetes

Belgium
Novo Nordisk A/S

Completed

Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus (ReFLeCT)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Switzerland, Denmark, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Novo Nordisk A/S

Completed

A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Malaysia, Mexico, Turkey, Thailand, Korea, Republic of
Novo Nordisk A/S

Completed

Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin (COMMIT)

Diabetes Mellitus, Type 2 | Diabetes

Slovakia
Novo Nordisk A/S

Completed

Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin

Diabetes Mellitus, Type 2 | Diabetes

Czech Republic
Wake Forest University Health Sciences
National Institute on Aging (NIA); General Electric

Completed

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (SNIFF-Quick)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus (CAN-TREAT)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Canada
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects

Healthy | Diabetes

China
Novo Nordisk A/S

Completed

A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

India

3

Subscribe